|
1
|
Stathis A and Moore MJ: Advanced
pancreatic carcinoma: Current treatment and future challenges. Nat
Rev Clin Oncol. 7:163–172. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Huang P, Chubb S, Hertel LW, Grindey GB
and Plunkett W: Action of 2′,2′-difluorodeoxycytidine on DNA
synthesis. Cancer Res. 51:6110–6117. 1991.PubMed/NCBI
|
|
3
|
Gresham GK, Wells GA, Gill S, Cameron C
and Jonker DJ: Chemotherapy regimens for advanced pancreatic
cancer: A systematic review and network meta-analysis. BMC Cancer.
14:4712014. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Vacchelli E, Eggermont A, Sautès-Fridman
C, Galon J, Zitvogel L, Kroemer G and Galluzzi L: Trial watch:
Oncolytic viruses for cancer therapy. Oncoimmunology. 2:e246122013.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Sze DY, Reid TR and Rose SC: Oncolytic
virotherapy. J Vasc Interv Radiol. 24:1115–1122. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Forbes NE, Krishnan R and Diallo JS:
Pharmacological modulation of anti-tumor immunity induced by
oncolytic viruses. Front Oncol. 4:1912014. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Chiocca EA and Rabkin SD: Oncolytic
viruses and their application to cancer immunotherapy. Cancer
Immunol Res. 2:295–300. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Nakao A, Kasuya H, Sahin TT, Nomura N,
Kanzaki A, Misawa M, Shirota T, Yamada S, Fujii T, Sugimoto H, et
al: A phase I dose-escalation clinical trial of intraoperative
direct intratumoral injection of HF10 oncolytic virus in
non-resectable patients with advanced pancreatic cancer. Cancer
Gene Ther. 18:167–175. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Hecht JR, Bedford R, Abbruzzese JL, Lahoti
S, Reid TR, Soetikno RM, Kirn DH and Freeman SM: A phase I/II trial
of intratumoral endoscopic ultrasound injection of ONYX-015 with
intravenous gemcitabine in unresectable pancreatic carcinoma. Clin
Cancer Res. 9:555–561. 2003.PubMed/NCBI
|
|
10
|
Mulvihill S, Warren R, Venook A, Adler A,
Randlev B, Heise C and Kirn D: Safety and feasibility of injection
with an E1B-55 kDa gene-deleted, replication-selective adenovirus
(ONYX-015) into primary carcinomas of the pancreas: A phase I
trial. Gene Ther. 8:308–315. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Wennier S, Li S and McFadden G: Oncolytic
virotherapy for pancreatic cancer. Expert Rev Mol Med. 13:e182011.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Russell SJ, Federspiel MJ, Peng KW, Tong
C, Dingli D, Morice WG, Lowe V, O'Connor MK, Kyle RA, Leung N, et
al: Remission of disseminated cancer after systemic oncolytic
virotherapy. Mayo Clin Proc. 89:926–933. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Carlson SK, Classic KL, Hadac EM, Dingli
D, Bender CE, Kemp BJ and Russell SJ: Quantitative molecular
imaging of viral therapy for pancreatic cancer using an engineered
measles virus expressing the sodium-iodide symporter reporter gene.
AJR Am J Roentgenol. 192:279–287. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Bossow S, Grossardt C, Temme A, Leber MF,
Sawall S, Rieber EP, Cattaneo R, von Kalle C and Ungerechts G:
Armed and targeted measles virus for chemovirotherapy of pancreatic
cancer. Cancer Gene Ther. 18:598–608. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Ellerhoff TP, Berchtold S, Venturelli S,
Burkard M, Smirnow I, Wulff T and Lauer UM: Novel
epi-virotherapeutic treatment of pancreatic cancer combining the
oral histone deacetylase inhibitor resminostat with oncolytic
measles vaccine virus. Int J Oncol. 49:1931–1944. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Awano M, Fujiyuki T, Shoji K, Amagai Y,
Murakami Y, Furukawa Y, Sato H, Yoneda M and Kai C: Measles virus
selectively blind to signaling lymphocyte activity molecule has
oncolytic efficacy against nectin-4-expressing pancreatic cancer
cells. Cancer Sci. 107:1647–1652. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Weiland T, Lampe J, Essmann F, Venturelli
S, Berger A, Bossow S, Berchtold S, Schulze-Osthoff K, Lauer UM and
Bitzer M: Enhanced killing of therapy-induced senescent tumor cells
by oncolytic measles vaccine viruses. Int J Cancer. 134:235–243.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Berchtold S, Lampe J, Weiland T, Smirnow
I, Schleicher S, Handgretinger R, Kopp HG, Reiser J, Stubenrauch F,
Mayer N, et al: Innate immune defense defines susceptibility of
sarcoma cells to measles vaccine virus-based oncolysis. J Virol.
87:3484–3501. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Skehan P, Storeng R, Scudiero D, Monks A,
McMahon J, Vistica D, Warren JT, Bokesch H, Kenney S and Boyd MR:
New colorimetric cytotoxicity assay for anticancer-drug screening.
J Natl Cancer Inst. 82:1107–1112. 1990. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Mosmann T: Rapid colorimetric assay for
cellular growth and survival: Application to proliferation and
cytotoxicity assays. J Immunol Methods. 65:55–63. 1983. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Kärber G: Beitrag zur kollektiven
Behandlung pharmakologischer Reihenversuche. Archiv für Experiment
Pathol und Pharmakol. 162:480–483. 1931. View Article : Google Scholar
|
|
22
|
Spearman C: The method of ‘Right and Wrong
Cases’ (Constant Stimuli) without Gauss's formula. Br J Psychol.
2:227–242. 1908.
|
|
23
|
Noll M, Berchtold S, Lampe J, Malek NP,
Bitzer M and Lauer UM: Primary resistance phenomena to oncolytic
measles vaccine viruses. Int J Oncol. 43:103–112. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Wennier ST, Liu J, Li S, Rahman MM, Mona M
and McFadden G: Myxoma virus sensitizes cancer cells to gemcitabine
and is an effective oncolytic virotherapeutic in models of
disseminated pancreatic cancer. Mol Ther. 20:759–768. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Krizhanovsky V, Xue W, Zender L, Yon M,
Hernando E and Lowe SW: Implications of cellular senescence in
tissue damage response, tumor suppression, and stem cell biology.
Cold Spring Harb Symp Quant Biol. 73:513–522. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Rodier F and Campisi J: Four faces of
cellular senescence. J Cell Biol. 192:547–556. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Skelding KA, Barry RD and Shafren DR:
Enhanced oncolysis mediated by Coxsackievirus A21 in combination
with doxorubicin hydrochloride. Invest New Drugs. 30:568–581. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Angelova AL, Aprahamian M, Grekova SP,
Hajri A, Leuchs B, Giese NA, Dinsart C, Herrmann A, Balboni G,
Rommelaere J and Raykov Z: Improvement of gemcitabine-based therapy
of pancreatic carcinoma by means of oncolytic parvovirus H-1PV.
Clin Cancer Res. 15:511–519. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Eisenberg DP, Adusumilli PS, Hendershott
KJ, Yu Z, Mullerad M, Chan MK, Chou TC and Fong Y: 5-fluorouracil
and gemcitabine potentiate the efficacy of oncolytic herpes viral
gene therapy in the treatment of pancreatic cancer. J Gastrointest
Surg. 9:1068–1079. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Hertel LW, Boder GB, Kroin JS, Rinzel SM,
Poore GA, Todd GC and Grindey GB: Evaluation of the antitumor
activity of gemcitabine (2′,2′-difluoro-2′-deoxycytidine). Cancer
Res. 50:4417–4422. 1990.PubMed/NCBI
|
|
31
|
Wang H, Chen NG, Minev BR, Zimmermann M,
Aguilar RJ, Zhang Q, Sturm JB, Fend F, Yu YA, Cappello J, et al:
Optical detection and virotherapy of live metastatic tumor cells in
body fluids with vaccinia strains. PLoS One. 8:e711052013.
View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Yurttas C, Berchtold S, Malek NP, Bitzer M
and Lauer UM: Pulsed versus continuous application of the prodrug
5-fluorocytosine to enhance the oncolytic effectiveness of a
measles vaccine virus armed with a suicide gene. Hum Gene Ther Clin
Dev. 25:85–96. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Singh HM, Ungerechts G and Tsimberidou AM:
Gene and cell therapy for pancreatic cancer. Expert Opin Biol Ther.
15:505–516. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Zamarin D, Holmgaard RB, Subudhi SK, Park
JS, Mansour M, Palese P, Merghoub T, Wolchok JD and Allison JP:
Localized oncolytic virotherapy overcomes systemic tumor resistance
to immune checkpoint blockade immunotherapy. Sci Transl Med.
6:226ra322014. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Engeland CE, Grossardt C, Veinalde R,
Bossow S, Lutz D, Kaufmann JK, Shevchenko I, Umansky V, Nettelbeck
DM, Weichert W, et al: CTLA-4 and PD-L1 checkpoint blockade
enhances oncolytic measles virus therapy. Mol Ther. 22:1949–1959.
2014. View Article : Google Scholar : PubMed/NCBI
|
